Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212323 · ClinicalTrials.gov registry record
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
A clinical trial of Smoldering Multiple Myeloma, sponsored by University of Utah.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06212323: Recruiting study of Smoldering Multiple Myeloma, sponsored by University of Utah.
NCT06212323 is a study of Smoldering Multiple Myeloma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 100 participants, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212323, a study of Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
Primary Outcome
Frequency and nature of progression events in a prospective cohort of patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI
Conditions Studied
Interventions
- OTHER Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
Study Locations (1)
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-11 |
| Est. Completion | 2030-03 |
What NCT06212323 shows while recruiting
NCT06212323 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. is the first listed.
NCT06212323 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06212323 about?
NCT06212323 is a clinical study titled "Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial". The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
What is the current status of trial NCT06212323?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-01-11. Estimated completion is 2030-03.
What conditions does trial NCT06212323 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT06212323?
The interventions under investigation include: Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. (OTHER).
Who is sponsoring clinical trial NCT06212323?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212323 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06212323's enrollment target sits among peer trials
100 11th of 20 higher than 10 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI